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Jia and colleagues have concluded that plasma endostatin shows a useful value for predicting failure to recover from acute kidney injury (AKI) [1] . They studied two populations of patients with AKI following non-cardiac major surgery, with the primary endpoint of recovery or "non-recovery" from AKI. Patients classified as "non-recovery" from AKI in fact consisted of two groups, a cohort receiving renal replacement therapy (RRT) at day 7 and another cohort without RRT [1] . We would like to make some comments. Endostatin, the C-terminal fragment of collagen XVIII, is a cytokine with a molecular weight of 20 kDa [2] . It stands to reason that this small molecule can be easily removed by RRT as the cutoff point of filter membranes is about 35 kDa [3] . According to the authors, patients with renal recovery showed endostatin concentrations of 62.6 ng/ml, whereas patients failing to recover showed higher concentrations of 108.5 ng/ml [1] . Also, almost 20% of the AKI population received RRT for 7 days [1] . Considering that endostatin can be removed by RRT, the endostatin values in this group of patients may fall significantly [3] . This could give the clinician the false impression that the patient will recover from AKI. Accordingly, if endostatin is used as a predictive tool in the future, falsely low endostatin values in RRT patients could lead to a premature de-escalation of care for intensive care unit (ICU) patients. There has been no investigation of the performance of endostatin in patients who receive RRT. Therefore, we believe there is a critical need for a future study with a focus on the performance of the currently known sepsis biomarkers in patients who receive RRT [4] . As noted by experts in endostatin, there is not enough evidence to date to support the use of endostatin measurements in clinical practice [5] . RRT is a good example of one of those conditions [5] .
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In this study, endostatin plasma concentration was detected immediately after acute kidney injury (AKI) diagnosis and before the renal replacement therapy (RRT) started and showed a useful value to predict the recovering from AKI failure. Early prediction aims to enable individual treatments and effective interventions that may improve clinical outcomes. Endostatin is a 28-kDa molecule that can be removed by a high flux membrane [6] . Different filtration membranes with different bore diameters can remove different sizes of a molecule. The clearance of the biomarker is significantly dependent on the molecule size and its sieving coefficient. This article did not evaluate the performance of the biomarker in RRT; thus, we did not analyze renal recovery according to plasma endostatin concentration during RRT. Further studies may be conducted to explore this issue in the future.
